Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Reports First Quarter 2018 Financial Results
-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $95.4 Million in the First Quarter- -ADCETRIS Approved by FDA in Frontline Stage III/IV Classical Hodgkin Lymphoma- -ECHELON-2 Data Expected in 2018- -Conference Call Today at 4:30 p.m. ET - BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 12, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 5, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a
View HTML
Toggle Summary Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Mar. 26, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , “Astellas”) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy Designation to
View HTML
Toggle Summary Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
First FDA-Approved Regimen in Frontline Stage III or IV Classical Hodgkin Lymphoma in More Than 40 Years FDA Approval Based on Clinical Trial Results from the Phase 3 ECHELON-1 Clinical Trial Label Expansion Represents Fifth Indication for ADCETRIS in the U.S.; ECHELON-1 Trial Also Converts Prior
View HTML
Toggle Summary Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 15, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth , Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry,
View HTML
Toggle Summary Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 13, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time . The presentation will be webcast live and available for
View HTML
Toggle Summary Seattle Genetics Completes Acquisition of Cascadian Therapeutics
-Transaction Provides Global Rights to Tucatinib, a Potentially Best-in-Class Tyrosine Kinase Inhibitor for HER2-Positive Metastatic Breast Cancer- -Ongoing Pivotal Trial HER2CLIMB Expected to Complete Enrollment in 2019- BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the “Offer”) by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
View HTML
Toggle Summary Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 7, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a
View HTML